Watch Gene Therapy Webinar Now!
The US FDA recently approved bluebird bio’s cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. This is very exciting news and we know many members of the thalassemia community have questions about it.
Dr. Sujit Sheth, Chief of the Division of Pediatric Hematology/Oncology and Professor of Clinical Pediatrics at Weill Cornell Medicine, presented information concerning the medical aspects of gene therapy during a live webinar on Wednesday, October 5, 2022. Representatives from bluebird bio also provided more information on matters related to Zynteglo and its availability.
For more information about Zynteglo, its availability, side effects, and coverage, please visit my bluebird support—a collection of educational resources and support services.